Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis

Gut

Volumn 64, Issue 4, 2015, Pages 673-683

  Verbeek, Jef ^a   Lannoo, Matthias ^a   Pirinen, Eija ^b,c   Ryu, Dongryeol ^b   Spincemaille, Pieter ^d   Elst, Ingrid Vander ^a   Windmolders, Petra ^a   Thevissen, Karin ^d   Cammue, Bruno P A ^d,e   Van Pelt, Jos ^a   Fransis, Sabine ^f   Van Eyken, Peter ^f   Groote, Chantal Ceuterick De ^g   Van Veldhoven, Paul P ^d   Bedossa, Pierre ^h   Nevens, Frederik ^a   Auwerx, Johan ^b   Cassiman, David ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b EPFL   (Switzerland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f DEPARTMENT OF CARDIOLOGY   (Belgium)

^g UNIVERSITY OF ANTWERP   (Belgium)

^h BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ADENOSINE TRIPHOSPHATE; CHOLESTEROL; CYTOCHROME C OXIDASE; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE DIET; CONTROLLED STUDY; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; GASTROSTOMY; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; LIPID DIET; LIVER FIBROSIS; LIVER MITOCHONDRION; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NYLON SUTURE; OBESITY; POLYGLACTIN SUTURE; PRIORITY JOURNAL; ROUX EN Y GASTRIC BYPASS; STOMACH BYPASS; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; HUMAN; LIVER DISEASE; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; GASTRIC BYPASS; HUMANS; INSULIN RESISTANCE; LIVER DISEASES; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA, LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924364818     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-306748     Document Type: Article

References (35)

1. Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013;58:593-608.
2. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52.
3. Cassiman D, Jaeken J. NASH may be trash. Gut 2008;57:141-4.
4. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52:1836-46.
5. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141:1249-53.
6. Targher G, Day C, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50.
7. Centis E, Marzocchi R, Suppini A, et al. The role of lifestyle change in the prevention and treatment of NAFLD. Curr Pharm Des 2013;19:5270-9.
8. Musso G, Gambino R, Cassader M, et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104.
9. Verbeek J, Cassiman D, Lannoo M, et al. Treatment of non-alcoholic fatty liver disease: can we already face the epidemic? Acta Gastroenterol Belg 2013;76:200-9.
10. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009;137:532-40.
11. Lassailly G, Caïazzo R, Pattou F, et al. Bariatric surgery for curing NASH in the morbidly obese? J Hepatol 2013;58:1249-51.
12. Dixon JB, Straznicky NE, Lambert EA, et al. Surgical approaches to the treatment of obesity. Nat Rev Gastroenterol Hepatol 2011;8:429-37.
13. Chavez-Tapia N, Tellez-Avila F, Barrientos-Gutierrez T, et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; (1): CD007340.
14. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011;8:35-44.
15. Anstee QM. Animal models in nonalcoholic steatohepatitis research: utility and clinical translation. Liver Int 2011;31:440-2.
16. Begriche K, Massart J, Robin MA, et al. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 2013;58:1497-507.
17. Andreux PA, Houtkooper RH, Auwerx J. Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov 2013;12:465-83.
18. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
19. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
20. Sanyal AJ, Brunt EM, Kleiner DE, et al . Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344-53.
21. Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012;56:1751-9.
22. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
23. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006;127:1109-22.
24. Gambino R, Musso G, Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal 2011;15:1325-65.
25. Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res 2013;52:175-91.
26. Charlton M, Krishnan A, Viker K, et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011;301: G825-34.
27. Kohli R, Kirby M, Xanthakos SA, et al . High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010;52:934-44.
28. Ishimoto T, Lanaspa MA, Rivard CJ, et al. High fat and high sucrose (western) diet induce steatohepatitis that is dependent on fructokinase. Hepatology 2013;58:1632-43.
29. Abdelmalek MF, Lazo M, Horska A, et al. Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology 2012;56:952-60.
30. Schuppan D, Pinzani M. Anti-fibrotic therapy: lost in translation? J Hepatol 2012;56 (Suppl 1):S66-74.
31. Rosselli M, MacNaughtan J, Jalan R, et al. Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut 2013;62: 1234-41.
32. Kohli R, Setchell KD, Kirby M, et al. A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology 2013;154:2341-51.
33. Cummings BP, Bettaieb A, Graham JL, et al. Bile-acid-mediated decrease in endoplasmic reticulum stress: a potential contributor to the metabolic benefits of ileal interposition surgery in UCD-T2DM rats. Dis Model Mech 2013;6:443-56.
34. Bell LN, Temm CJ, Saxena R, et al. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg 2010;251:1041-8.
35. Immonen H, Hannukainen JC, Iozzo P, et al . Effect of bariatric surgery on liver glucose metabolism in morbidly obese diabetic and non-diabetic patients. J Hepatol 2014;60:377-83.